JP Morgan Chase
MRKR icon

JP Morgan Chase’s Marker Therapeutics MRKR Stock Holding History

JP Morgan Chase’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34 Hold
23
– – ﹤0.01% 7606
2026
Q1 		$29 Hold
23
– – ﹤0.01% 7392
2025
Q4 		$34 Hold
23
– – ﹤0.01% 7271
2025
Q3 		$21 Sell
23
-192
-89% -$237 ﹤0.01% 7283
2025
Q2 		$329 Buy
215
+179
+497% +$230 ﹤0.01% 6742
2025
Q1 		$44 Sell
36
-2
-5% -$4 ﹤0.01% 7004
2024
Q4 		$119 Hold
38
– – ﹤0.01% 6984
2024
Q3 		$107 Hold
38
– – ﹤0.01% 6992
2024
Q2 		$206 Hold
38
– – ﹤0.01% 6782
2024
Q1 		$164 Buy
38
+5
+15% +$22 ﹤0.01% 6833
2023
Q4 		$182 Sell
33
-801
-96% -$2.71K ﹤0.01% 7061
2023
Q3 		$3.84K Buy
834
+711
+578% +$3.97K ﹤0.01% 6416
2023
Q2 		$381 Hold
123
– – ﹤0.01% 6567
2023
Q1 		$0 Sell
123
-1
-0.8% -$2 ﹤0.01% 7044
2022
Q4 		$0 Sell
124
-5
-4% -$17 ﹤0.01% 6825
2022
Q3 		$0 Buy
129
+5
+4% +$18 ﹤0.01% 6707
2022
Q2 		$0 Hold
124
– – ﹤0.01% 6723
2022
Q1 		$0 Hold
124
– – ﹤0.01% 6859
2021
Q4 		$1K Hold
124
– – ﹤0.01% 6563
2021
Q3 		$2K Hold
124
– – ﹤0.01% 6333
2021
Q2 		$4K Sell
124
-3,624
-97% -$95.4K ﹤0.01% 6154
2021
Q1 		$83K Sell
3,748
-2,306
-38% -$52.8K ﹤0.01% 5419
2020
Q4 		$87K Buy
6,054
+4,851
+403% +$75.3K ﹤0.01% 5033
2020
Q3 		$19K Buy
1,203
+107
+10% +$1.95K ﹤0.01% 5159
2020
Q2 		$23K Buy
1,096
+127
+13% +$2.78K ﹤0.01% 5009
2020
Q1 		$18K Sell
969
-21
-2% -$535 ﹤0.01% 4972
2019
Q4 		$29K Buy
990
+2
+0.2% +$73 ﹤0.01% 5256
2019
Q3 		$50K Buy
988
+144
+17% +$8.51K ﹤0.01% 5177
2019
Q2 		$65K Buy
+844
New +$50.1K ﹤0.01% 5078
2018
Q4 		– Hold
0
– – – 5833
2018
Q3 		– Hold
0
– – – 5758

Other funds holding MRKR

BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase's MRKR Position: Q2 2026 in Review

JP Morgan Chase held its Marker Therapeutics (MRKR) position steady in Q2 2026 at 23 shares worth $34. The position accounts for ﹤0.01% of the portfolio, ranked #7606.

JP Morgan Chase first reported a position in MRKR in Q2 2019 and has held it in 29 quarters since. The position peaked at $87K in Q4 2020. 25 funds tracked by Wall St. Rank hold MRKR as of Q2 2026.

  • JP Morgan Chase held 23 shares of Marker Therapeutics worth $34 as of Q2 2026.
  • JP Morgan Chase left its Marker Therapeutics share count unchanged in Q2 2026.
  • Marker Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7606 holding.
  • JP Morgan Chase first reported a position in Marker Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • JP Morgan Chase's Marker Therapeutics position peaked at $87K in Q4 2020.
  • 25 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.